BigHat Doses First Patient With an AI Designed CDH17 ADC in Phase 1
BigHat Biosciences dosed the first patient on 1 September 2026 in a Phase 1 study of BHB810, an AI designed CDH17 directed ADC for gastrointestinal cancers. Oncology R&D teams should watch whether developability choices from the platform survive early human safety and pharmacokinetic readouts.
What changed
On 1 September 2026, BigHat Biosciences announced the first patient has been dosed in a Phase 1 trial of BHB810, a CDH17 directed VHH Fc antibody drug conjugate for gastric and other advanced gastrointestinal cancers. BigHat says BHB810 is the first clinical program from its AI powered antibody design platform.
The company engineered BHB810 for potent activity against CDH17 expressing tumors while aiming for a differentiated safety profile and favorable manufacturability. The first in human dose escalation study will evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity, starting with advanced gastric and gastroesophageal junction tumors.
BigHat reports that across nearly 30 patient and cell derived tumor models, including gastric cancers with low or heterogeneous CDH17 expression, BHB810 drove complete or near complete tumor clearance in preclinical work.
Why it matters
CDH17 has been a difficult oncology target; a clinically dosed ADC designed with an AI first workflow is a concrete test of whether computational antibody platforms can shorten the path from target to human proof. For pharma R&D leaders, the readout is not just efficacy signals but whether AI guided developability choices hold up under real manufacturing and dosing constraints.
Positive Phase 1 safety and pharmacokinetic data would strengthen the case for AI assisted biologics in solid tumors where traditional discovery cycles remain long and attrition heavy.
Who is affected
Oncology drug development executives evaluating in silico design vendors. ADC program managers watching CDH17 competition. Clinical operations teams enrolling gastrointestinal cancer patients in early phase trials. Investors tracking AI biotech platforms that have moved beyond preclinical press releases into human dosing.
What to do next
If you partner with AI antibody shops, compare BigHat's disclosed preclinical package against your internal developability gates before assuming platform transferability. Monitor trial registry updates for cohort expansion timing and any published safety narratives that reference manufacturing or immunogenicity surprises.
What to watch
Initial safety and dose escalation readouts from the Phase 1 study. Competitor CDH17 programs and whether BigHat publishes correlation between AI design hypotheses and clinical biomarker response.
Sources
- Primary. BioSpace / BigHat Biosciences, First patient dosed in Phase 1 trial of BHB810 (1 September 2026). Trial start, target, platform claim, and preclinical scope.